|
|
Mupirocin
(¹«ÇǷνÅ)
|
|
|
|
Therapeutic Classification |
- Antibiotics; Miscellaneous
|
|
Mechanism of Action |
¼¼±ÕÀÇ isoleucyl t-RNA synthetase¿¡ °áÇÕÇÏ¿© ´Ü¹é ¹× RNA ÇÕ¼ºÀ» ¾ïÁ¦ÇÑ´Ù.
|
|
Clinical Uses |
Staphylococcus aureus, ¥â-¿ëÇ÷¼º ¿¬¼â»ó±¸±Õ, S. pyogenes·Î ÀÎÇÑ ³ó°¡Áø Ä¡·á¿¡ ¿Ü¿ë
|
|
Pharmacokinetics |
- Èí¼ö : ¿Ü¿ë : ÇǺΠ»óÃþÀº Åë°úÇÏÁö¸¸ Á¤»óÇǺο¡¼ Àü½ÅÈí¼ö´Â °ÅÀÇ ÀϾÁö ¾Ê´Â´Ù.
- ´Ü¹é°áÇÕ : 95%
- ´ë»ç : °£, ÇǺο¡¼ ´ëºÎºÐÀÌ monic acid·Î ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 17-36ºÐ
- ¼Ò½Ç : ½Å¹è¼³
|
|
Usual Dosage |
¼Ò¾Æ ¹× ¼ºÀÎ : ¿Ü¿ë : 5-14 ÀÏ°£ ¼Ò·®À» 1ÀÏ 2-5 ȸ ȯºÎ¿¡ Àû¿ë
|
|
Adverse Reactions |
- °¡²û ÀϾ´Â ºÎÀÛ¿ë
- ±¹¼Ò : ÀÛ¿°¨, ÀÚÅë, ¾ÐÅë, ºÎÁ¾, ÅëÁõ
- ÇǺΠ: ¼Ò¾çÁõ, ¹ßÁø, È«¹Ý, ÇǺΰÇÁ¶
|
|
Contraindications |
- º» ¾à¹°¿¡ °ú¹Î¼º
- Polyethylene glycol ÇÔÀ¯ Á¦Á¦´Â ÀڱؼºÀÌ ÀÖÀ¸¸ç µ¿¹°À̳ª ¼¼Æ÷¹è¾ç½Ã ÀÌÇü¼ºÀ» À¯¹ßÇϹǷΠ¼Õ»óµÈ ÇǺγª Á¡¸·¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
- Polyethylene glycolÀ» ÇÔÀ¯ÇÑ Á¦Á¦´Â ½Åµ¶¼ºÀÇ À§ÇèÀÌ ÀÖÀ¸¹Ç·Î Å« °³¿»óÀ̳ª Ȼ󿡴 »ç¿ëÇÏÁö ¾Ê´Â´Ù.
- ´«¿¡´Â Àû¿ëÇÏÁö ¾Ê´Â´Ù.
|
|
Precautions |
- ½ÉÇÑ È»óÀ̳ª °³¿»óÀÌ Àִ ȯÀÚ¿¡°Ô Àû¿ë½Ã ºÎÇüÁ¦·Î ÇÔÀ¯µÈ polyethylene glycolÀÌ µ¶¼º ¿ë·®±îÁö °æÇǸ¦ ÅëÇØ Èí¼öµÉ ¼ö ÀÖ´Ù.
- Àå±â°£ »ç¿ë½Ã ºñ°¨¼ö¼º ±ÕÀÌ °úµµÇÏ°Ô Áõ½ÄµÉ ¼ö ÀÖ´Ù.
- ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù.
- ¾ÐÅë Ä¡·á¿¡ »ç¿ëÇÏÁö ¾Ê´Â´Ù.
|
|
Stability |
¹èÇÕºÒ°¡ : Aquaphor , coal tar ¿ë¾×, salicylic acid
|
|
Patient Education |
- ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇØ¾ß ÇÑ´Ù.
- ´«¿¡ Àû¿ëÇÏÁö ¸»¾Æ¾ß ÇÑ´Ù.
- ¹ßÁø, °¡·Á¿òÁõ, Àڱذ¨ÀÌ ³ªÅ¸³ª¸é »ç¿ëÀ» Áß´ÜÇÑ´Ù.
- º¸Åë 5ÀÏ À̳»¿¡ Áõ»óÀÌ °³¼±µÈ´Ù.
|
|
Additional Information |
- ³ëÀÎÀÇ ¾ÐÅë Ä¡·á¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù.
- Polyethylene glycolÀ» ºÎÇüÁ¦·Î ÇÔÀ¯ÇÑ´Ù.
|
|
|
|